Isocitrate Dehydrogenase Inhibitor Targeting Mutant IDH2
Solution Overview
Problem
Current treatments for cancers characterized by mutant isocitrate dehydrogenase 2 (IDH2) lack effective inhibitors that can specifically target and inhibit the enzyme's aberrant activity, leading to the production of 2-Hydroxyglutarate, which contributes to cancer development.
Innovation Solution
Development of a compound represented by formula (I), a pharmaceutically acceptable salt, crystal, or solvate, which acts as a potent inhibitor of mutant IDH2, inhibiting its enzyme activity and tumor cell growth, specifically designed to target mutations at residues R140 or R172.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancers with mutant IDH2, then general cancer treatment is provided, but specific inhibition of mutant IDH2 enzyme activity and 2-Hydroxyglutarate production is not achieved
Solution Approach 1:
The compound is designed to specifically target and bind to the mutant IDH2 enzyme structure, exploiting local structural differences caused by mutations at residues R140 or R172. The molecular structure contains specific functional groups that interact with the mutant active site, providing selective inhibition while leaving wild-type IDH2 unaffected.
Solution Approach 2:
The invention changes the chemical parameters of the inhibitor to optimize binding affinity for mutant IDH2. By modifying molecular weight, functional group composition, and stereochemical configuration, the compound achieves enhanced specificity and potency against mutant IDH2 compared to existing inhibitors.
2Reliability
If IDH2 inhibitors are developed to reduce 2-Hydroxyglutarate production, then cancer development is inhibited, but the complexity of drug development increases
Solution Approach 1:
The compound serves multiple therapeutic functions simultaneously: it inhibits mutant IDH2 enzyme activity, reduces 2-Hydroxyglutarate production, and suppresses tumor cell growth. This multi-functionality is achieved through a single molecular entity that targets the root cause of the disease mechanism.
Solution Approach 2:
The inhibitor acts as an intermediary molecule that blocks the interaction between mutant IDH2 and its substrate alpha-ketoglutarate. By occupying the active site, the compound mediates the inhibition of the neomorphic activity that produces excessive 2-Hydroxyglutarate, thereby preventing cancer development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits mutant IDH2 enzyme activity and tumor cell growth, offering a therapeutic option for cancers such as glioblastoma, acute myeloid leukemia, and other IDH2 mutation-associated tumors by reducing 2-Hydroxyglutarate production.
Implementation Method 1
the compound effectively inhibits mutant IDH2 enzyme activity... which acts as a potent inhibitor of mutant IDH2, inhibiting its enzyme activity
Data Source
Figure 1
AI summary
Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.